Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections and Bloodstream Infections Caused by Staphylococcus aureus: A Comprehensive Review of the Evidence [PDF]
, 2022 Corcione, Silvia +1 more
core +1 more source
Innovative Tools and in vivo Methods for Tuberculosis Drug Discovery and Development [PDF]
, 2019 Worldwide, tuberculosis (TB) is the leading cause of death due to a single infectious agent, claiming 1.6 million human lives and causing >10 million new cases in 2017 alone, mostly in low-income regions.
Sommer, Raphael Christopher
core +1 more source
, 2023 Objective: Contezolid is an oxazolidinone antimicrobial agent newly approved for treatment of Gram-positive bacterial infections. It is primarily metabolized by the liver. This study aimed to assess whether it is required to adjust the dose of contezolid
Hailan Wu (10203665) +9 more
core +2 more sources
Frontiers in PediatricsBackgroundInitial choices of antimicrobial therapy for most cases of community-acquired pneumonia (CAP) in children under 5 years of age are typically based on local epidemiology, risk factors assessment, and subsequent clinical parameters and positive ...
Hui-Ying Liu +15 more
doaj +1 more source
The gut microbiota in liver transplantation recipients during the perioperative and postoperative recovery period [PDF]
BackgroundChronic Liver Disease (CLD) is one of the frequent causes of death, especially in the developing world. Liver transplantation (LT) is an effective modality to treat end-stage liver disease.
Jun Xu +5 more
core +1 more source
Design and Synthesis of Novel Antibacterial Agents [PDF]
, 2021 The latest data on antimicrobial resistance (AMR) related mortality is alarming. A conservative estimate places current global death due to AMR infections at 700,000 annually and projections anticipate that this could rise to 10 million by 2050.
Tan, Jinlong
core
697. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06) [PDF]
, 2019 Background Contezolid (MRX-I) is an oxazolidinone in development for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). In this study, in vitro susceptibility (S) for Contezolid and comparator agents for Gram-
Demei Zhu, Fupin Hu, Yang Yang
core +1 more source
Antimicrobial Resistance and Artificial Intelligence Applications [PDF]
The computational comprehension of intelligent behavior is the main goal of the scientific and engineering field of artificial intelligence (AI). Many human professions, particularly clinical diagnosis and prognosis, greatly benefit from artificial ...
Zahraa khalid Al- kheroo
core +1 more source
686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06) [PDF]
, 2019 Background Contezolid (MRX-I) is an oxazolidinone in development for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). In this study, in vitro susceptibility (S) for Contezolid and comparator agents for Gram-
Demei Zhu, Yang Yang
core +1 more source